A new computational tool could help researchers identify promising drug combinations for treating cancer, according to a new ...

If the Superior Court rejects the application to raise it to the Supreme Court, GSK and the other defendants ... and it was also sold in generic form by several other producers.

The global orally disintegrating tablet market size was valued at USD 14.76 billion in 2024 and is projected to grow from USD 16.33 billion in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7 ...

Scientists have developed retriever, a computational tool that extracts disease-specific drug response signatures to predict the best combinations for cancer treatment.

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK PLC on Monday said the European Medicines Agency accepted for review its application for an alternative treatment ... Subscribe now to see this Premium News article from Alliance News ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

It has also been sold in generic form by several other producers, some of which have also been named in litigation, including Boehringer Ingelheim, Pfizer, and Johnson & Johnson. GSK's settlement ...

Teva Pharmaceutical Industries Ltd. ADR-0.62% $20.28B ...